R&D leaders grapple with decisions about programme ... For a typical portfolio of a leading pharmaceutical company, assuming a composition of 75% small molecules and 25% biologics distributed ...

Markus Gershater looks at how automation and artificial intelligence (AI) can transform pharma R&D. Due to increasing complexity in R&D, pharma teams are under pressure to drive down costs and ...

is yet more proof that this is an area on the cusp of the pharmaceutical R&D mainstream. That was one of the key messages from SynBioBeta’s Synthetic Biology Biopharma Conference last month ...

Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing. Fosun Pharma’s ...

However, fast-selling GLP-1 medications are also bringing more R&D energy back to the small molecule arena with wider patient pools. Amid this backdrop, here are the forces shaping pharma’s ...

In the 20th century, pharmaceutical manufacturers made massive R&D investments in a collective quest to discover the next generation of lifesaving medications. Among those innovations were birth ...

Pharmaceutical and hospital sector executives are requesting higher public healthcare spending, R&D incentives, and tax ...

as will aligning R&D, medical affairs, and commercial functions to ensure seamless execution across the value chain. In addition, pharmaceutical companies should focus on elevating business acumen ...

Shares of Sun Pharma Advanced Research (SPARC) are higher by more than 13% on December 16, after the management said it plans to share an 'update' on its clinical programs as well as the R&D ...